Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
McKinsey
Harvard Business School
AstraZeneca

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ETOMIDATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Etomidate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00175747 A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed National Cancer Institute (NCI) Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00175747 A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed University of British Columbia Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00248729 Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital. Completed St. Luke's Hospital, Pennsylvania Phase 2 2002-10-01 The objective of this study was to compare the utility of etomidate and midazolam in helping patients to relax when there was a need for the placement of a ventilation tube by medics who were transporting patients to a hospital in an ambulance.
NCT00415701 Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed University Hospital Inselspital, Berne Phase 4 2006-11-01 The purpose of this study is to evaluate the effect of a single dose of etomidate for patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB adrenocortical responsiveness, on requirements of hemodynamic support, and on use of intensive care resources.
NCT00440102 Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity Completed Assistance Publique - Hôpitaux de Paris Phase 4 2007-04-01 The expected benefit is a reduction of the morbidity of patients admitted in the intensive care unit having received ketamine for intubation.
NCT00441792 The Effect of Etomidate on Patient Outcomes After Single Bolus Doses Completed Emergency Medicine Foundation N/A 2007-10-01 The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.
NCT00441792 The Effect of Etomidate on Patient Outcomes After Single Bolus Doses Completed Advocate Hospital System N/A 2007-10-01 The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etomidate

Condition Name

Condition Name for Etomidate
Intervention Trials
Anesthesia 4
Hemodynamics 3
Depression 3
Hemodynamic Instability 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Etomidate
Intervention Trials
Depression 4
Coronary Disease 3
Coronary Artery Disease 3
Pain, Postoperative 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Etomidate

Trials by Country

Trials by Country for Etomidate
Location Trials
United States 19
China 10
Poland 4
France 4
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Etomidate
Location Trials
Minnesota 3
California 2
Pennsylvania 2
Florida 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Etomidate

Clinical Trial Phase

Clinical Trial Phase for Etomidate
Clinical Trial Phase Trials
Phase 4 35
Phase 3 2
Phase 2/Phase 3 4
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Etomidate
Clinical Trial Phase Trials
Completed 29
Unknown status 13
Recruiting 11
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Etomidate

Sponsor Name

Sponsor Name for Etomidate
Sponsor Trials
Tianjin Medical University General Hospital 3
Medical University of Lublin 2
Tang-Du Hospital 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Etomidate
Sponsor Trials
Other 66
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
AstraZeneca
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.